Phthalates, including di(2-ethylhexyl)
phthalate (
DEHP), are widely used and have been linked with the development of
wheezing and
asthma. The main metabolite of
DEHP, mono-2-ethylhexyl
phthalate (
MEHP), was investigated for adjuvant effects in a mouse inhalation model. BALB/cJ mice were exposed to
aerosols of 0.03 or 0.4 mg/m(3)
MEHP 5 days/week for 2 weeks and thereafter weekly for 12 weeks together with a low dose of
ovalbumin (OVA) as a model
allergen. Mice exposed to OVA alone or OVA+Al(
OH)(3) served as negative and positive controls, respectively. Finally, all groups were exposed to a nebulized 1% OVA
solution on 3 consecutive days to investigate the development of an inflammatory response. Serum, bronchoalveolar lavage (BAL) fluid, and draining lymph nodes were collected 24h later. In the OVA+Al(
OH)(3) group, significantly increased levels of OVA-specific
IgE and
IgG1 in serum as well as of eosinophils in BAL fluid were observed. OVA-specific
IgG1 production in both
MEHP groups was significantly increased. OVA-specific
IgE and
IgG2a were not increased significantly. A dose-dependent increase in inflammatory cells was observed in BAL fluid, leading to significantly higher lymphocyte and eosinophil numbers in the OVA+0.4 mg/m(3)
MEHP group. Ex vivo
cytokine secretion by cultures of draining lymph nodes suggested a T(H)2 profile of
MEHP. In conclusion,
MEHP acted as a T(H)2 adjuvant after inhalation. However, it is suggested that the
inflammation in the
MEHP groups was primarily mediated by an IgG1-dependent mechanism. To address implications for humans, a margin-of-exposure was estimated based on the lack of significant effects on
IgE production and
inflammation after exposures to 0.03 mg/m(3)
MEHP observed in the present study and estimated human exposure levels.